Barclays
RNAM

Barclays’s Avidity Biosciences RNAM Stock Holding History

Barclays’s Portfolio RNAM Stock Details RNAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-60,000
Closed -$2.45M – 5443
2024
Q2 		$2.45M Buy
+60,000
New +$1.72M ﹤0.01% 1998

Other funds holding RNAM

CC
Corsicana & Co Corsicana, Texas $158M AUM

Barclays's RNAM Position: Q1 2026 in Review

Barclays sold out of Avidity Biosciences (RNAM) in Q1 2026, closing a stake of 531,203 shares — an estimated $38.3M sold.

Barclays first reported a position in RNAM in Q1 2022 and held it in 16 quarters. The position peaked at $38.3M in Q4 2025. 1 fund tracked by Wall St. Rank holds RNAM as of Q1 2026.

  • Barclays reported no remaining Avidity Biosciences position as of Q1 2026 after selling out during the quarter.
  • Barclays sold 531,203 Avidity Biosciences shares in Q1 2026, an estimated $38.3M.
  • Barclays first reported a position in Avidity Biosciences in Q1 2022 and held it in 16 quarters.
  • Barclays's Avidity Biosciences position peaked at $38.3M in Q4 2025.
  • 1 fund tracked by Wall St. Rank held Avidity Biosciences as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.